SUVN-502 data being presented at 16th BioPartnering in London

HYDERABAD, INDIA (October 13, 2008) – Suven Life Science is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products, which are first in class or best in class therapies through the use of GPCR targets for CNS disorders with unmet medical need and high market potential, today announced that it is scheduled to present at the 16th Annual Bio Partnering Europe on 14th Oct 2008.

Mr. Venkat Jasti CEO of Suven Life Sciences is scheduled to discuss the company’s business strategy, corporate overview and to present the data on their lead Phase 1 clinical candidate SUVN-502  for cognition in Alzheimer’s and Schizophrenia at 1.30 pm at the QE11 Conference Centre, London, UK where the world’s most innovative companies present themselves to a targeted audience of decision makers.


Suven Life Sciences has six internally discovered therapeutic drug candidates currently in clinical and pre-clinical stage of development targeting conditions such as ADHD, dementia, and depression, Huntington's disease. Parkinson's disease and obesity are in addition to developmental candidates in Alzheimer's disease and Schizophrenia.


Risk Statement:
Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this news release may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive.
 

Posted: October 2008

View comments

Hide
(web1)